Nephro Care India Limited

As of March 31, 2026, Nephro Care India Limited carries a market capitalization of 853.17M, placing it among publicly traded companies globally. Its enterprise value stands at 688.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Nephro Care India Limited has 16.49M shares outstanding.

As of March 31, 2026, Nephro Care India Limited trades at a trailing price-to-earnings ratio of 59.28. The price-to-sales ratio is 1.95, and the price-to-book ratio stands at 1.50.

These figures are as of March 31, 2026. The EV/Sales ratio of 1.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 688.65M versus a market cap of 853.17M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Nephro Care India Limited maintains a current ratio of 2.02, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Nephro Care India Limited posted a return on equity (ROE) of 2.54, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -4.11, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 2.04, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 2.58, useful for judging operating efficiency across full business cycles. Inventory turnover of 6.33 indicates how many times Nephro Care India Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Nephro Care India Limited recorded 4.34M in income tax expense. That works out to an effective tax rate of 23.34, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 18.59M, leaving 14.25M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Nephro Care India Limited's stock has declined approximately 40.74% over the past 52 weeks. The 50-day moving average sits at 90.08, while the 200-day moving average is 82.05.

Over the twelve months ended March 31, 2026, Nephro Care India Limited generated 434.09M in revenue and converted that into 14.25M in net income, yielding earnings per share of 0.87. EBITDA reached -508,000.00, while operating income came in at -30.14M.

These figures are as of March 31, 2026. Total book value stands at 568.54M, with working capital of 155.11M providing operational flexibility.

Over the twelve months ended March 31, 2026, Nephro Care India Limited posted a gross margin of 67.42, reflecting its pricing power and cost economics. The operating margin of -6.94 and net profit margin of 3.28 provide insight into operational efficiency.